Celebrating International Clinical Trials Day

 

Why diagnostics? Innovation is key to expanding access to diagnostic testing in low- and middle-income countries, and to defeating some of the world’s most challenging infectious diseases – from COVID-19 to tuberculosis (TB), hepatitis C virus (HCV), neglected tropical diseases (NTDs), and antimicrobial resistance (AMR). 

Why clinical trials? To ensure the development of quality diagnostics, policy makers and regulatory bodies depend on reliable evidence, strong performance evaluations, and implementation strategies. This is not possible without robust clinical trials that assess diagnostic performance in and across relevant populations and settings.

 

Did you know? In 2021, over 60,000 participants enrolled in FIND-supported studies across 186 sites in 25 countries.

On International Clinical Trials Day, we want to thank every single person involved in these trials. Whether participant or researcher, you are helping drive new developments in diagnostics that can, and will, protect millions of lives.

 

The role of biobanks: Before clinical evaluations in real-life settings can take place, biological samples are used to advance and accelerate product development. To better understand that complex process, we invite you to watch our 60-second animation and read short stories developed with experts.

In 2008, we started expanding our biobank services to improve access to high-quality, well-characterized samples, and support academics, non-profits, and developers with the testing and development of new diagnostic tools.  

Read on to discover more about the progress we’ve made this past year.

First sample collections made available through our decentralized biobank model  

In 2021, we started work to build a network of FIND Integrated Biobanks across Africa, South-East Asia, South America, and Europe. 

As part of this, June 2021 saw COVID-19 samples collected by Peru’s Universidad Peruana Cayetano Heredia – the first member of the network – made available to support global efforts for test development. In December (just a few weeks after the Omicron variant was first reported) we were also able to provide samples from the University of Cape Town, South Africa for developers to test existing diagnostics against this new variant.

Virtual biobank operationalized for COVID-19 and expanding to NTDs

Late 2020, we launched the new DxConnect Virtual Biobank, an open-access resource connecting institutions that store samples with diagnostic developers all over the world.

  • Learn more about how the virtual biobank can maximize existing resources and stimulate collaboration in this Nature Biotechnology article.
  • Read the interview or watch the webinar organized by the International Society for Neglected Tropical Diseases to find out how the DxConnect Virtual Biobank can contribute towards the WHO 2030 roadmap targets for NTDs.

Specimen bank expansion

Last year, we expanded our Specimen Bank to include fever samples – adding to our collection of over 500,000 samples to support diagnostic developments in COVID-19, TB, malaria, HCV, and AMR.

  • Learn more about the samples and services we provide in this 360Dx article.

Take action

We are currently looking for new partners to work with us and support the FIND Specimen Bank. Check out our request for proposal.

 

If you’re interested in advancing the evaluation and development of diagnostic tools and want to find out more about our broader partnership opportunities, please contact Warren.Fransman@finddx.org.

We look forward to hearing from you. 

Warren Fransman, Senior Manager, Specimen Bank &

Pamela Nabeta, Senior Manager, Clinical Affairs

 

FIND
Campus Biotech, Chemin des Mines 9

1202 Geneva, Switzerland

www.finddx.org

Unsubscribe